고위험 초기 단계 삼중 음성 또는 호르몬 수용체-로우 양성/HER-2 음성 유방암을 가진 참가자의 다른 항암제와 함께 Patritumab Deruxtecan + Pembrolizumab의 연구 (MK-1022-010, Herthena-Breast-03)
개방형 무작위 2 상 연구는 카보 플라 틴/파클리탁셀 + 펨브 롤리 주맙과 비교하여 화학 요법과 함께 수술 및 수술 및 보조 펨브 롤리 주 맙에 이어 펨브 롤리 주맙과 비교하여 카보 플라 틴/파클리탁셀 플러스 펨브 롤리 주맙 전후에 투여 된 Patritumab deruxtecan + pembrolizumab의 안전성 및 효능을 평가하기위한 2 상 무작위 2 상 연구. 음성 또는 호르몬 수용체-낮은 양성/인간 표피 성장 인자 수용체 -2 음성 유방암 (Herthena-Breast03)
Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn:
- About the safety of the study treatments and if people tolerate them
- If people who receive patritumab deruxtecan, pembrolizumab, and chemotherapy before surgery have fewer cancer cells removed during surgery compared to those who receive only pembrolizumab (pembro) and chemotherapy.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Toll Free Number
- 전화번호: 1-888-577-8839
- 이메일: Trialsites@msd.com
연구 장소
-
-
-
Taichung, 대만, 407
- 모병
- Taichung Veterans General Hospital ( Site 2502)
-
연락하다:
- Study Coordinator
- 전화번호: +886423592525
-
Tainan, 대만, 704
- 모병
- National Cheng Kung University Hospital ( Site 2503)
-
연락하다:
- Study Coordinator
- 전화번호: +88662353535
-
Taipei, 대만, 112
- 모병
- Koo Foundation Sun Yat-Sen Cancer Center ( Site 2501)
-
연락하다:
- Study Coordinator
- 전화번호: 886228970011x1686
-
-
-
-
-
Seoul, 대한민국, 03080
- 모병
- Seoul National University Hospital ( Site 2400)
-
연락하다:
- Study Coordinator
- 전화번호: +82220720850
-
Seoul, 대한민국, 05505
- 모병
- Asan Medical Center ( Site 2401)
-
연락하다:
- Study Coordinator
- 전화번호: +82230103217
-
Seoul, 대한민국, 03722
- 모병
- Severance Hospital, Yonsei University Health System ( Site 2402)
-
연락하다:
- Study Coordinator
- 전화번호: +82222288135
-
-
-
-
California
-
Santa Monica, California, 미국, 90404
- 모병
- UCLA Hematology/Oncology - Parkside ( Site 0021)
-
연락하다:
- Study Coordinator
- 전화번호: 424-402-9520
-
-
Illinois
-
Skokie, Illinois, 미국, 60077
- 모병
- Orchard Healthcare Research Inc. ( Site 0006)
-
연락하다:
- Study Coordinator
- 전화번호: 847-568-9932
-
-
Montana
-
Billings, Montana, 미국, 59102
- 모병
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003)
-
연락하다:
- Study Coordinator
- 전화번호: 406-238-6685
-
-
Oregon
-
Happy Valley, Oregon, 미국, 97015
- 모병
- Northwest Cancer Specialists, P.C. ( Site 8003)
-
연락하다:
- Study Coordinator
- 전화번호: 360-944-9889
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37203
- 모병
- SCRI Oncology Partners ( Site 7000)
-
연락하다:
- Study Coordinator
- 전화번호: 844-482-4812
-
-
Texas
-
Dallas, Texas, 미국, 75246
- 모병
- Texas Oncology - DFW ( Site 8000)
-
연락하다:
- Study Coordinator
- 전화번호: 214-370-1067
-
Houston, Texas, 미국, 77030
- 모병
- Houston Methodist Hospital ( Site 0022)
-
연락하다:
- Study Coordinator
- 전화번호: 713-441-9948
-
-
Virginia
-
Norfolk, Virginia, 미국, 23502
- 모병
- Virginia Oncology Associates (VOA) ( Site 8001)
-
연락하다:
- Study Coordinator
- 전화번호: 844-482-4812
-
-
-
-
-
Córdoba, 스페인, 14004
- 모병
- Hospital Universitario Reina Sofia ( Site 1702)
-
연락하다:
- Study Coordinator
- 전화번호: +34 957012408
-
-
Catalonia
-
Badalona, Catalonia, 스페인, 08916
- 모병
- Institut Català d'Oncologia (ICO) - Badalona ( Site 1700)
-
연락하다:
- Study Coordinator
- 전화번호: +34934978925
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, 스페인, 28027
- 모병
- Clinica Universidad de Navarra ( Site 1703)
-
연락하다:
- Study Coordinator
- 전화번호: +34913531920
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has locally advanced, non-metastatic (M0), breast cancer, defined as any of the following combined primary tumor (T) and regional lymph node (N) staging per current American Joint Committee on Cancer (AJCC) criteria: cT1c, N1-N2; cT2, N0-N2; cT3, N0-N2; or cT4a-d, N0-N2
- Has centrally confirmed diagnosis of breast cancer that is triple-negative or HR-low+/HER2- breast cancer that will be treated according to the triple-negative breast cancer (TNBC) paradigm
- Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load
- Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 28 days prior to allocation/randomization
- Has left ventricular ejection fraction (LVEF) of ≥50% or ≥ lower limit of normal (LLN) as assessed by echocardiogram (ECHO) or multigate acquisition scan (MUGA) scan
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has uncontrolled or significant cardiovascular disease before randomization
- Has any history of or evidence of any current leptomeningeal carcinomatosis.
- Has clinically significant corneal disease
- Has human immunodeficiency virus (HIV) infection with a history of Kaposi sarcoma and/or multicentric Castleman disease
- Has evidence of ongoing, uncontrolled, systemic bacterial, fungal, or viral infection
- Has received prior therapy with an anti-programmed death (PD)-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor
- Has received any prior treatment, including radiation, systemic therapy, and/or definitive surgery for currently diagnosed breast cancer
- Has received prior treatment with an anti-human epidermal growth factor receptor 3 (HER3) antibody and/or antibody-drug conjugate (ADC) that consists of an exatecan derivative that is a topoisomerase I inhibitor (e.g., trastuzumab deruxtecan)
- Has metastatic (Stage IV) breast cancer or cN3 nodal involvement
- Has known additional malignancy that is progressing or has required active treatment within the past 5 years
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, or current or suspected ILD
- Has an active infection requiring systemic therapy
- Has concurrent active HBV and HCV infection
- Has clinically severe respiratory compromise resulting from intercurrent pulmonary illness
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Part 1, A: Pembrolizimab + patritumab deruxtecan → Pembrolizumab + paclitaxel + carboplatin
In Part 1, participants receive neoadjuvant pembrolizumab 200 mg via intravenous (IV) infusion every 3 weeks (Q3W) plus patritumab deruxtecan via IV infusion Q3W for 12 weeks, followed by pembrolizumab 200 mg via IV infusion Q3W plus paclitaxel 80 mg/m^2 via IV infusion every week (QW) and carboplatin AUC1.5 mg/ml/min via IV infusion QW for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. |
Administered via IV infusion as neoadjuvant treatment
다른 이름들:
Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
다른 이름들:
Administered via IV infusion as neoadjuvant treatment
다른 이름들:
Administered via IV infusion as neoadjuvant treatment
다른 이름들:
|
|
실험적: Part 2, A: Pembrolizimab + patritumab deruxtecan → Pembrolizumab + paclitaxel + carboplatin
In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion every Q3W plus patritumab deruxtecan (dose to be determined in part 1) IV infusion Q3W for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min IV infusion QW for 12 weeks. At 3-6 weeks after last dose of neoadjuvant treatment, participants undergo surgery for breast cancer. After surgery, participants receive adjuvant pembrolizumab 400 mg IV every 6 weeks (Q6W) for ~30 weeks. Additional adjuvant treatment of physician's choice (TPC) may be given to participants with residual disease. TPC options are olaparib 300 mg oral twice daily (BID) for 1 year (participants with germline BRCA mutation [gBRCAm] only), capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles or doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV Q3W or every 2 weeks (Q2W) and cyclophosphamide 600 mg/m^2 IV Q3W or Q2W for 4 doses. |
Administered via IV infusion as neoadjuvant treatment
다른 이름들:
Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
다른 이름들:
Administered via IV infusion as neoadjuvant treatment
다른 이름들:
Administered via IV infusion as neoadjuvant treatment
다른 이름들:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
다른 이름들:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
다른 이름들:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
다른 이름들:
Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2
다른 이름들:
Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2
다른 이름들:
|
|
실험적: Part 2, B: Pembrolizumab + paclitaxel + carboplatin → Pembrolizumab + patritumab deruxtecan
In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min IV infusion QW for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus patritumab deruxtecan (dose to be determined in part 1) via IV infusion Q3W for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will receive adjuvant pembrolizumab 400 mg IV infusion Q6W for ~30 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options include olaparib 300 mg oral BID for 1 year (participants with gBRCAm only), capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles or doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV infusion Q3W or Q2W and cyclophosphamide 600 mg/m^2 IV infusion Q3W or Q2W for 4 doses. |
Administered via IV infusion as neoadjuvant treatment
다른 이름들:
Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
다른 이름들:
Administered via IV infusion as neoadjuvant treatment
다른 이름들:
Administered via IV infusion as neoadjuvant treatment
다른 이름들:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
다른 이름들:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
다른 이름들:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
다른 이름들:
Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2
다른 이름들:
Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2
다른 이름들:
|
|
활성 비교기: Part 2, C: Pembro + paclitaxel + carboplatin→ Pembro + doxorubicin (or epirubicin) +cyclophosphamide
In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min via IV infusion QW for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV infusion Q3W and cyclophosphamide 600 mg/m^2 IV infusion Q3W for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will receive adjuvant pembrolizumab 400 mg IV infusion Q6W for approximately 30 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options include olaparib 300 mg oral BID for 1 year (participants with gBRCAm only) or capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles. |
Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
다른 이름들:
Administered via IV infusion as neoadjuvant treatment
다른 이름들:
Administered via IV infusion as neoadjuvant treatment
다른 이름들:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
다른 이름들:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
다른 이름들:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
다른 이름들:
Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2
다른 이름들:
Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Part 1: Number of Participants Experiencing an Adverse Event (AE)
기간: Up to ~43 weeks
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented for Part 1. |
Up to ~43 weeks
|
|
Part 1: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)
기간: Up to 21 days
|
A DLT is defined by the National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) Version 5.0, assessed by investigator as drug-related: Grade (gr) 3 or 4 nonhematologic toxicity (with exceptions); gr 3 or gr 4 laboratory values (with exceptions); gr 3 or 4 febrile neutropenia; prolonged delay (>2 weeks) in initiating Cycle 2 (cycle length = 3 weeks) due to intervention-related toxicity; any intervention-related toxicity that causes the participant to discontinue intervention during Cycle 1; interstitial lung disease as per investigator; any other gr ≥3 pulmonary toxicity; or gr 5 toxicity. |
Up to 21 days
|
|
Part 1: Number of Participants who Discontinued Study Treatment Due to an AE
기간: Up to ~30 weeks
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinued study treatment due to an AE will be presented for Part 1. |
Up to ~30 weeks
|
|
Part 2: Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0
기간: Up to ~30 weeks
|
pCR (ypT0/Tis ypN0) is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy at the time of definitive surgery. |
Up to ~30 weeks
|
|
Part 2: Number of Participants Experiencing an AE
기간: Up to ~103 weeks
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented for Part 2. |
Up to ~103 weeks
|
|
Part 2: Number of Participants who Discontinued Study Treatment Due to an AE
기간: Up to ~90 weeks
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinued study treatment due to an AE will be presented for Part 2. |
Up to ~90 weeks
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Part 2: pCR-No Ductal Carcinoma in Situ (DCIS) Rate Using the Definition of ypT0 ypN0
기간: Up to ~30 weeks
|
pCR-no DCIS (ypT0 ypN0) is defined as the absence of residual invasive and in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy at the time of definitive surgery. |
Up to ~30 weeks
|
|
Part 2: Event-Free Survival (EFS)
기간: Up to ~100 months
|
EFS is defined as the time from randomization to disease progression that precludes surgery, local or distant recurrence, or death due to any cause, whichever occurs first. |
Up to ~100 months
|
|
Part 2: Overall Survival (OS)
기간: Up to ~100 months
|
OS is defined as the time from randomization to date of death due to any cause. |
Up to ~100 months
|
|
Part 2: Distant Progression or Distant Recurrence-Free Survival (DPDRFS)
기간: Up to ~100 months
|
DPDRFS is defined as the time from randomization to first distant progression or distant recurrence event as assessed or death due to any cause, whichever occurs first. |
Up to ~100 months
|
|
Part 2: Residual Cancer Burden (RCB)
기간: Up to ~30 weeks
|
RCB is defined as residual disease in either the breast or lymph node at the time of surgery. RCB score provides a continuous measurement of the extent of residual cancer. There are four RCB classes: RCB-0 (RCB score 0), RCB-1 (0< RCB score <1.36), RCB-2 (1.36 <RCB score <3.28), and RCB-3 (RCB score >3.28). |
Up to ~30 weeks
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 연구 책임자: Medical Director, Merck Sharp & Dohme LLC
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 부위별 신생물
- 신생물
- 피부병
- 유방 질환
- 피부 및 결합 조직 질환
- 유방 신생물
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 핵산, 뉴클레오티드 및 뉴 클레오 시드
- 탄화수소
- 사이클로 파라핀
- 탄화수소, alicyclic
- 탄화수소, 순환
- 테르펜
- 탄수화물
- 다 환식 방향족 탄화수소
- 탄화수소, 방향족
- 다 환식 화합물
- 글리코 사이드
- 조정 복합체
- 박습니다
- 사이클로 데카네
- Diterpenes
- 데 옥시 시티 딘
- 시티 딘
- 피리 미딘 뉴 클레오 시드
- 피리 미딘
- 포스 포 아미드 머스타드
- 질소 머스타드 화합물
- 겨자 화합물
- 탄화수소, 할로겐화
- 포스 포 아미드
- 유기 인 화합물
- 뉴 클레오 시드
- 우라실
- 피리 미디 논
- 안트라 사이클린
- 나프 타센
- 아미노 글리코 시드
- Daunorubicin
- 데 옥시 리보 뉴 클레오 시드
- Fluorouracil
- 카페시타빈
- 시클로포스파미드
- 카르보플라틴
- 독소루비신
- 파클리탁셀
- 에피루비신
- 펨브 롤리 주맙
- 올라 파리브
- Patritumab deruxtecan
기타 연구 ID 번호
기타 연구 ID 번호
- 1022-010
- MK-1022-010 (기타 식별자: MSD)
- U1111-1307-7867 (레지스트리 식별자: UTN)
- 2024-514376-40-00 (레지스트리 식별자: EU CT)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .